HC Wainwright & Co. Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $14

2024-08-22 19:40

HC Wainwright & Co. analyst Yi Chen initiates coverage on Orchestra BioMed Hldgs (NASDAQ: OBIO) with a Buy rating and announces Price Target of $14.

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。